In the largest randomized DBPC trial of anti-IL-5 therapy in EoE to date, 226 pediatric subjects received reslizumab and, again, significant improvements in clinical symptoms were not seen in the treatment arm compared to placebo (38). This evidence concerns the gene IL5 and eosinophilic esophagitis.